Clinical data on the compassionate use of B-VEC to treat a RDEB patient, with recurrent cicatrizing conjunctivitis that leads to conjunctival scarring, at the Bascom Palmer Eye Institute

PITTSBURGH, April 13, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will be presenting new data on the compassionate use of topical beremagene geperpavec (B-VEC) to treat a patient with dystrophic epidermolysis bullosa (DEB) with recurrent cicatrizing conjunctivitis at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting being held from April 23-27, 2023 in New Orleans, LA.

Presentation details are as follows:

Title: Topical beremagene geperpavec (B-VEC) for the treatment of recurrent cicatrizing conjunctivitis in a patient with dystrophic epidermolysis bullosa
Presenter: Alfonso L. Sabater, M.D., PhD, University of Miami Health System Bascom Palmer Eye Institute, Miami, FL
Session: Gene therapy and gene editing for ocular disorders
Date and Time: April 23, 2023 from 12:00PM to 1:45PM CST
Presentation Number: C0388

The poster will be available to conference attendees. Following the presentation, materials will be available to view online on the Investor section of the Company’s website.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The Company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. Headquartered in Pittsburgh, Pennsylvania, the Company is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.

CONTACT

Investors and Media:                                                                
Meg Dodge                                                      
Krystal Biotech                                                    
This email address is being protected from spambots. You need JavaScript enabled to view it.